Price T Rowe Associates Inc Spectrum Pharmaceuticals Inc Transaction History

Price T Rowe Associates Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.38 - $1.07 $2,449 - $6,897	-6,446 Reduced 18.55%	28,305 $22,000
Q4 2022 Feb 14, 2023	SELL	$0.32 - $0.52 $192 - $312	-601 Reduced 1.7%	34,751 $13,000
Q3 2022 Nov 14, 2022	SELL	$0.43 - $1.56 $2,406 - $8,729	-5,596 Reduced 13.67%	35,352 $16,000
Q2 2022 Aug 15, 2022	SELL	$0.7 - $1.4 $9,854 - $19,709	-14,078 Reduced 25.58%	40,948 $32,000
Q1 2022 May 16, 2022	BUY	$0.63 - $1.59 $4,016 - $10,136	6,375 Added 13.1%	55,026 $71,000
Q4 2021 Feb 14, 2022	SELL	$1.27 - $2.42 $76,521 - $145,812	-60,253 Reduced 55.33%	48,651 $62,000
Q3 2021 Nov 15, 2021	SELL	$2.15 - $3.82 $45,580 - $80,984	-21,200 Reduced 16.29%	108,904 $237,000
Q2 2021 Aug 16, 2021	BUY	$2.89 - $4.45 $12,750 - $19,633	4,412 Added 3.51%	130,104 $488,000
Q1 2021 May 17, 2021	BUY	$2.9 - $4.09 $7,078 - $9,983	2,441 Added 1.98%	125,692 $410,000
Q4 2020 Feb 16, 2021	BUY	$3.38 - $5.14 $416,588 - $633,510	123,251 New	123,251 $420,000

115K

Ticker SPPI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,164,000
Description
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor ...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.